Preclinical Assessment Core (PAC)

总结 COBRE南卡罗来纳州转化研究中心的一个主要目的是改善肌肉骨骼 健康（SC-TRIMH）是为了促进和实现针对骨和关节疾病的研究和创新， 改善病人护理。动物模型和人尸体模型是验证 肌肉骨骼研究假设，是诊断的临床前评估策略所固有的 和治疗，用于新技术评估，并用于计算模型的验证。使命 临床前评估核心（PAC）的目的是为SC-TRIMH提供指导和战略规划 研究者使用活的大型动物模型和/或人尸体模型， 研究项目。它提供SC-TRIMH所需的专业设施、专业知识和资源 研究人员进一步评估其体外进展进入临床实践的潜力。在COBRE第一阶段， PAC在克莱姆森大学和PRISMA卫生系统中整合了独特的资源和专业知识 (PHS)一个由专家和服务组成的综合网络，分为两个互补的重点： 动物建模（LAM）和人类尸体建模（HCM）。LAM包括最先进的生物医学 研究和动物成像设施在AAALAC认可的戈德利-斯内尔研究中心和 克莱姆森农场也可提供用于肌肉骨骼研究的各种动物模型 为SC-TRIMH研究者开发新模型提供了灵活性。多年来，克莱姆森 大学，通过其生物工程系，已经建立了一个令人印象深刻的组合肌肉骨骼创新 使用大型动物模型进行研究，为第一阶段的PAC能力奠定了基础。HCM推力， 位于克莱姆森大学生物医学工程创新校区（CUBEInC），包括生物技能 外科培训和创新中心和其他资源。作为克莱姆森的健康创新中心 大学自2011年以来，CUBEInC位于PRISMA卫生系统骨科患者诊所上方， 物理治疗在第一阶段，PAC将CUBEInC的资源和专业知识纳入其培训计划 在技术开发和成熟以及初创公司发展和指导方面， 提高SC-TRIMH调查人员对创新周期的认识。PAC领导团队由 由著名的临床医生和科学家，以及设施管理人员组成的支持小组， 技术专家和科学家。在第二阶段，项目咨询委员会将继续向所有人提供技术指导和支持， SC-TRIMH研究者，尤其是那些不具备临床前评估专业知识的研究者， 正朝着成为来自南方的肌肉骨骼研究人员的主要翻译资源的方向发展。 卡罗莱纳和其他地方。PAC的具体目标是：（1）继续提供专业知识和支持， 临床建模，2）继续担任初级研究者临床前研究的促进者，以及3）进一步 加强和提高体内和体外临床前研究能力，以支持SC-TRIMH。

SUMMARY A major purpose of the COBRE South Carolina Center for Translational Research for Improving Musculoskeletal Health (SC-TRIMH) is to promote and enable research and innovation addressing bone and joint disorders for the improvement of patient care. Animal models and human cadaveric models are essential for verifying musculoskeletal research hypotheses, and are intrinsic to the pre-clinical assessment strategy for diagnostics and treatments, for novel technology evaluation, and for the verification of computational models. The mission of the Pre-clinical Assessment Core (PAC) is to provide mentoring and strategic planning to SC-TRIMH investigators for the use of live large animal models and/or human cadaver models in their musculoskeletal research programs. It provides the specialized facilities, expertise, and resources needed by SC-TRIMH investigators to further evaluate the potential of their in vitro advances into clinical practice. In COBRE Phase I, PAC has consolidated unique resources and expertise at Clemson University and the PRISMA Health System (PHS) into a comprehensive network of experts and services organized into two complementary thrusts: the Live Animal Modeling (LAM) and Human Cadaveric Modeling (HCM) thrusts. LAM includes state-of-art biomedical research and animal imaging facilities at the AAALAC-accredited Godley-Snell Research Center and the Clemson Farms enabling access to the full spectrum of animal models used in musculoskeletal research as well as flexibility for the development of novel models needed by SC-TRIMH investigators. Over the years, Clemson University, through its Bioengineering Department, has built an impressive portfolio of musculoskeletal innovative research using large animal models which laid the foundation for PAC capabilities in Phase I. The HCM thrust, located at the Clemson University Biomedical Engineering Innovation Campus (CUBEInC), includes the Bioskills Surgical Training and Innovation Center and other resources. As the health innovation hub for Clemson University since 2011, CUBEInC is located at the PRISMA Health System above orthopaedic patient clinics and physical therapy. In Phase I, PAC integrated into its training program, the CUBEInC's resources and expertise in technology development and maturation, as well as start-up company development and mentoring, further increasing awareness of SC-TRIMH investigators about the innovation cycle. The PAC leadership team consists of the thrusts' co-directors, both renowned clinicians and scientists, and a support group of facility managers, technical experts, and scientists. In Phase II, PAC will continue to provide technical mentoring and support to all SC-TRIMH investigators, especially those who do not have primary expertise in pre-clinical assessment, while progressing toward being the major translational resource for musculoskeletal researchers from across South Carolina and elsewhere. The specific aims of PAC are to 1) continue providing expertise and support for pre- clinical modeling, 2) continue serving as a facilitator for junior investigator pre-clinical research, and 3) further strengthen and enhance the in vivo and ex vivo pre-clinical research capability to support SC-TRIMH.